Infection Risk with Teclistamab in Multiple Myeloma: A Systematic Review and Meta-Analysis

Zeng-Yi Huang's systematic review and meta-analysis quantifies infection outcomes for relapsed/refractory multiple myeloma patients treated with teclistamab. The analysis includes five studies encompassing 714 patients, reporting pooled incidences of any-grade and grade ≥3 infections. The dataset was last updated on 2026-04-30.

Use Cases

• Quantify pooled infection incidence rates based on reported any-grade and grade ≥3 infection percentages.
• Compare infection outcomes between clinical trial and real-world evidence cohorts based on subgroup analysis results.
• Analyze factors contributing to infection heterogeneity based on variations in follow-up duration and IVIG prophylaxis rates mentioned in the description.

Strengths

• Includes data from five studies with a total of 714 patients, providing a defined sample size.
• Reports specific pooled incidence percentages with 95% confidence intervals for any-grade (56.5%) and grade ≥3 (27.6%) infections.
• Provides subgroup analysis comparing clinical trial (MajesTEC-1) and real-world evidence cohorts with specific risk percentages.

Limitations

• The dataset is a 254.0 KB PDF, which is a small document; the underlying structured data is not directly provided.
• Column-level documentation is absent; field semantics must be inferred from the text after download.
• Row count for any underlying tabular data is unknown, which may limit suitability assessment for computational analysis.

Provenance

Source

Zeng-Yi Huang via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, Web of Science, and the Cochrane Library.

Freshness

Last updated 2026-04-30 05:41:27; freshness should be verified.